scholarly journals Factors associated with breast cancer occurrence before the age of 40 in Yaoundé

2020 ◽  
Vol 9 (2) ◽  
pp. 782
Author(s):  
Felix Essiben ◽  
Esther JN Um Meka ◽  
Gregory Ayissi ◽  
Henri Essome ◽  
Etienne Atenguena ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Family History ◽  
Threshold Value ◽  
Screening Tests ◽  
Breast Cancers ◽  
Paediatric Hospital ◽  
Factors Associated ◽  
Balanced Diet ◽  
Significance Threshold

Background: In Cameroon, one third of breast cancers concern women less than 40 of age and young age appeared to be an independent predictor of adverse outcome. This study aimed to determine factors associated with the development of breast cancer before the age of 40 in Yaoundé.Methods: A case-control study was conducted for 7 months, from November 1st, 2016 to May 31st, 2017 at the General Hospital and the gyneco-obstetric and Paediatric Hospital of Yaoundé. Study compared the socio-demographic, clinical and lifestyle data of 50 women less than 40 of age with breast cancer (cases) with those of 200 women below 40 of age without breast cancer (controls). Descriptive statistics, bivariate and multivariate logistic regressions were performed to assess the socio-demographic, clinical and lifestyle data. Data were computed using the SPSS version 23.0 software. The significance threshold value was set at 0.05.Results: After multivariate analysis, the factors independently associated with the occurrence of breast cancer before the age of 40 were: age ≥ 30 (aOR = 2.05); family history of breast cancer (aOR = 8.65); parity ≥ 1 (aOR = 2.46); breastfeeding (aOR = 3.39); waist circumference ≥ 88 centimeters (cm) (aOR = 4.38); breast density ≥ 90                      (aOR = 2.89); physical activity ≤ 3 hours/week (aOR = 4.78). Conclusions: Breast cancer in women under 40 is associated with family history, reproductive life and women's lifestyles.  Breastfeeding more than 12 months, having a balanced diet, supplementary screening tests in women with dense breasts and practicing physical activity; would be  effective ways to prevent it in young women.

scholarly journals Biochemical Factors associated with Breast Cancer in Bangladeshi Women

2014 ◽  
Vol 6 (2) ◽  
pp. 58-62
Author(s):  
DAS Hussain ◽  
S Ahmed ◽  
M Hoque ◽  
SMR Rabbi ◽  
S Masood ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Family History ◽  
Cancer Patients ◽  
Blood Levels ◽  
Breast Cancer Patients ◽  
Blood Samples ◽  
Factors Associated ◽  
Medical College ◽  
Biochemical Features

Breast Cancer is the commonest maligrancy in woment. A study was carried out in the Department of Biochemistry, Dhaka Medical College to investigate some of the biochemical features that are associated with breast cancer occurring in Bangladeshi women. Thirty diagnosed breast cancer patients and thirty healthy women were selected. A questionnaire was used for collecting information regarding age, family history, physical activity and exercise, BMI, diet, smoking, alcohol abuse, addiction, details of menstrual and obstetric history, breast-feeding, parity, use of contraceptives and HRT. Blood samples were collected and tested for fasting lipid profiles, serum estrogen and progesterone. The study has revealed that high levels of serum total cholesterol (P<0.05), TAG (P<0.05), LDL-C (P<0.05) and low level of serum and HDL-C (P<0.05) were found to be associated with breast cancer. The study further reveals that blood levels of estrogen (P<0.05) and progesterone (P<0.05) were found to be lower than that of the controls. DOI: http://dx.doi.org/10.3329/bjmb.v6i2.17644 Bangladesh J Med Biochem 2013; 6(2): 58-62

scholarly journals Factors associated with breast MRI use among women with a family history of breast cancer

2018 ◽  
Vol 24 (5) ◽  
pp. 764-771 ◽  
Author(s):  
Mary C. White ◽  
Ashwini Soman ◽  
Clarice R. Weinberg ◽  
Juan L. Rodriguez ◽  
Susan A. Sabatino ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Breast Mri ◽  
Factors Associated ◽  
History Of

Prevalence and differentiation of hereditary breast and ovarian cancer in Japan.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 1534-1534
Author(s):  
Seigo Nakamura ◽  
Takuji Iwase ◽  
Seiichiro Nishimura ◽  
Hideko Yamauchi ◽  
Tadashi Nomizu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Family History ◽  
Brca1 Mutation ◽  
Information Service ◽  
Breast Cancers ◽  
Founder Mutations ◽  
Mutation Site ◽  
Luminal Type ◽  
The U.S

1534 Background: Breast cancer is the most common female cancer, according to the Center for Cancer Control and Information Service in Japan. However, the lifetime breast cancer risk in Japan is markedly lower (one in 16) than in the U.S. or Europe. We assembled needed data on the prevalence and characteristics of BRCA1/2 in Japan. Methods: Our study of BRCA 1 and 2 (BRCA1/2) collected data at 8 institutions in Japan on 320 individuals with a strong family history of breast cancer, according to the NCCN guidelines, by the end of March, 2012. Results: Among 260 proband cases, 46 (17.7%) were positive for BRCA1 and 35 (13.5%) were BRCA2 positive. Therefore, the total pathological mutation rate was 30.7%. Pathology data after breast surgery were obtained from 35 cases of BRCA1 mutation, 22 (62.9%) of which were triple negative and 10 (29.4%) were Luminal type. On the other hand, 24 cases (85.7%) of BRCA2 mutations were Luminal type. The most prevalent BRCA1 mutation site was L63X, found in 10 families. L63X was reported previously by studies in Japan, and it may be a founder mutation. We found 2 cases of large deletion detected by MLPA, comprising the first two reported cases in Japan. One was an entire deletion of exon 20 and the lacked exons 1-9. Eight cases of BRCA1 (3.1%) and 12 (4.6%) BRCA2 were uncertain variants. TN with a family history ovarian cancer were 14/20 (70%), TN under 40 y/o 17/23 (73.9%) and TN with one or more breast cancers in family history 19/32 (59.4%) showed higher incidences of BRCA1/2, especially BRCA1. Conclusions: HBOC may have nearly the same prevalence in Japan as in the U.S. or Europe. If TN cases are taken into account, the ratio of BRCA1 is higher. L63X may be one of the founder mutations in Japan. A nationwide database of HBOC is important to address these challenges: (1) To develop risk models for BRCA1/2 carriers in Japan (2) To identify the proper methods to detect cancer occurrence among Japanese BRCA1/2 carrier early (3) To differentiate whether uncertain mutation variants found in Japan are deleterious.

Factors associated with the incompliance with mammogram screening among individuals with a family history of breast cancer or ovarian cancer

2006 ◽  
Vol 101 (3) ◽  
pp. 317-324 ◽  
Author(s):  
Hongyu Wu ◽  
Kangmin Zhu ◽  
Ismail Jatoi ◽  
Mona Shah ◽  
Craig D. Shriver ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Family History ◽  
Factors Associated ◽  
History Of

Predicting risk of estrogen receptor positive breast cancers in postmenopausal women

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 1507-1507
Author(s):  
R. T. Chlebowski ◽  
G. L. Anderson ◽  
D. S. Lane ◽  
A. Aragaki ◽  
T. Rohan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Estrogen Receptor ◽  
Family History ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Breast Biopsy ◽  
Breast Cancers ◽  
Estrogen Receptor Positive

1507 Background: Chemoprevention strategies for estrogen receptor positive (ER+) breast cancers are emerging, especially for postmenopausal women, but require methods of targeting appropriate populations. Our objective was to improve the Breast Cancer Risk Assessment Tool [Gail Model (GM)] for estimating ER+ breast cancer risk. Methods: A prospective cohort involving 161,809 postmenopausal women aged 50–79 years, (93,676 in the observational study (OS) and 68,132 in clinical trials (CT)) at Women’s Health Initiative (WHI) Clinical Centers had comprehensive assessment of lifestyle, medication use and breast cancer risk factors. Breast cancer risk from the GM and other models incorporating additional or fewer risk factors and five year incidence of ER + and ER negative (ER-) invasive breast cancers were determined. Main outcome measures were concordance statistics for models predicting breast cancer risk. Results: Of 148,266 women meeting eligibility criteria, (no prior breast cancer and/or mastectomy), 3,236 developed breast cancer. Chronological age and age at menopause, both GM components, were significantly associated with only ER+ but not ER- breast cancer risk (p<0.05 for heterogeneity test). The GM predicted population-based ER+ cancer risk with reasonable accuracy (concordance statistic 0.60, 95% confidence interval (CI) 0.58 to 0.62) but for ER- cancers, the results were equivalent to chance allocation (concordance statistic 0.49, 95% CI 0.45 to 0.54). For ER+ cancers, no additional risk factors improved the GM prediction. However, a simpler model, developed in the OS and tested in the CT population, including only age, family history, and benign breast biopsy was comparable to GM in ER+ breast cancer prediction (concordance statistics 0.58, 95% CI 0.56 to 0.60). Using this model, all women ≥ 55 years old (or ≥ 60 year old if African American) with either a prior breast biopsy or first degree breast cancer family history had five year breast cancer risk of ≥ 1.8%. Conclusions: In postmenopausal women with comprehensive mammography use, the GM identifies populations at increased risk for ER+ breast cancer but not for ER- cancer. A model with fewer variables provides a simpler alternative for identifying populations appropriate for breast cancer chemoprevention interventions. No significant financial relationships to disclose.

A retrospective review of demographics and stage of triple-negative breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11553-e11553
Author(s):  
F. N. Rana
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Triple Negative Breast Cancer ◽  
Hormone Receptors ◽  
Triple Negative ◽  
Smoking Status ◽  
Linear Trend ◽  
Published Data ◽  
Breast Cancers ◽  
Demographic Risk

e11553 Background: Triple negative breast cancer (TNBC) is a recently recognized subtype of breast cancer, notable to metastasize early. It accounts for 15–20% of all breast cancers, and is more prevalent in African-American and Hispanic women, and women younger than 40 years of age. Continual decline in breast cancer deaths since 1990 has been attributed to earlier detection, better treatment including hormonal blockade in estrogen- and progesterone-receptor positive cancers, as well as the addition of Trastuzumab, a monoclonal antibody directed against the Her2/neu receptors. These hormone receptors are not found in TNBC, and therefore the traditional targets for endocrine manipulation cannot be therapeutically exploited. While lower socioeconomic status and racial predisposition to this disease have been observed, there exists a paucity of research into other demographic risk factors. We reviewed data between January 2000 to December 2005 from our tumor registry with particular attention to age, race, family history, tobacco use, and stage of presentation, comparing this subset of patients (n=39) to other records (n=303). We included only those patients in whom the status of all three receptors were recorded. Results: Comparisons were made for TNBC vs non-TNBC patients respectively as follows: mean age (59.87± yrs vs 60.09±yrs). Analysis using χ2 test (χ2=0.855) and CMH test for Linear Trend analysis (p=0.47) showed no difference in percentages in association with the 5 stages or TNBC status and no linear trend respectively. Conclusions: This data suggests that at our institution, TNBC is less prevalent (12.87%) than estimates of 15- 20% published in other studies. There was no difference in age at diagnosis (p=0.92), with black patients more likely to have TNBC (p=0.004, OR=2.75). There was no significant association between smoking status and TNBC (p=0.43). There was no significant association between a family history of cancer and TNBC (p=0.8384). When accounting for samples size, TNBC was as prevalent as non TNBC at all stages of diagnosis. These results differ from other published data and may reflect differences in statistical analysis. No significant financial relationships to disclose.

Predictors of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ (DCIS) who underwent evaluation for BRCA genetic testing.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1549-1549
Author(s):  
Nisreen Elsayegh ◽  
Angelica M. Gutierrez-Barrera ◽  
Kimberly I. Muse ◽  
Heather Lin ◽  
Diana L. Turco ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Genetic Counseling ◽  
Family History ◽  
Tumor Markers ◽  
Prophylactic Mastectomy ◽  
Contralateral Prophylactic Mastectomy ◽  
Educational Status ◽  
Nuclear Grade ◽  
Factors Associated ◽  
History Of

1549 Background: Patients with DCIS are at increased risk for developing contralateral breast cancer (CBC). Therefore, an increasing number of women with DCIS are electing for contralateral prophylactic mastectomy (CPM). In a previous study involving 2072 women with DCIS, 13.5% chose CPM. In this study, we aimed to evaluate factors associated with CPM in patients with DCIS who underwent genetic counseling for BRCA. Methods: 165 women with pure DCIS, who underwent genetic counseling, were included in the study. Patients’ characteristics were obtained from a prospectively maintained research database at UT M.D. Anderson Cancer Center. Univariate and multivaraite logistic regression analysis were used to determine predictive factors associated with CPM. Patients’ characteristics included age, marital and educational status, tumor markers, nuclear grade, family history with breast (BC) and ovarian cancer (OC), race, Ashkenazi Jewish ancestry, and BRCA genetic test results. Results: Out of 165 patients, 17(10.3%) were found to have a BRCA deleterious mutation. 44(26.7%) underwent CPM. Younger patients (median ≤ 45 yr) were more likely to elect for CPM than older patients (p= 0.0098). Patients who tested positive for a BRCA mutation were more likely to elect for CPM than those who tested negative or were not tested (p= 0.0001). Patients who had a family history of OC (15 (57.7%) were more likely to choose CPM than those who did not (p= 0.0004). These three factors remained significant in the multivariate model (p <0.008). Marital and educational status, tumor markers, nuclear grade, and family history of breast cancer were not significant predictors of CPM. Conclusions: The rate of CPM in patients with DCIS is high. Factors associated with increased likelihood of undergoing CPM include family history of OC, age, and BRCA positivity. Further studies are needed to evaluate patients perception of CBC risk, and if this may play a role in the high number of CPM.

Prophylactic mastectomy: The role of risk aversion.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 39-39
Author(s):  
Laura Kruper ◽  
Meghana Bhatt ◽  
Karin London ◽  
Katherine Henderson ◽  
Courtney Vito ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Marital Status ◽  
Prophylactic Mastectomy ◽  
Brca Mutation ◽  
Large Population ◽  
Factors Associated ◽  
Younger Age ◽  
History Of ◽  
Caucasian Patients

39 Background: The rate of women undergoing contralateral prophylactic mastectomy (CPM) has increased significantly over the past decade. Large population studies have examined factors associated with the use of CPM. We studied the factors associated with CPM within our institution. Methods: A 30-question validated survey was mailed to all patients who underwent mastectomy from 1972 to 2011 and are currently receiving treatment or surveillance at our institution. Responses were analyzed to determine the factors predictive of CPM. Multivariate logistic regression methods were used to calculate odds ratios (OR) and 95% confidence intervals (CI) for possible associations between exposures (including age at surgery, marital status, education, race, family history of breast cancer, and BRCA genetic mutation (BRCA mutation) and likelihood of CPM. Results: 368 of 691 surveys were returned. Younger age was statistically significantly associated with increased likelihood of CPM (p-trend < 0.001). Caucasian patients were 4 times as likely to undergo CPM compared to non-Caucasian patients (OR 3.95, 95%CI=1.89-8.23). Patients with a family history of breast cancer were 3 times as likely to undergo CPM as compared with those with no family history (OR 3.38, 95%CI=1.4-8.16). Married patients were also 3 times as likely to undergo CPM compared with unmarried patients (OR 3.00, 95%CI=1.39-6.52). Reporting a BRCA mutation was highly correlated with younger age, positive family history, higher level of education and marital status. Conclusions: When faced with the decision of whether to undergo a CPM, patients must assess both objective future risks and subjective feelings about those risks. These results suggest that the decision to undergo CPM is associated with known risk factors for the development of contralateral cancer such as younger age and positive breast cancer family history. In addition, multiple demographic factors including Caucasian race and married status increased the likelihood of choosing CPM. This may relate to social support as well socioeconomic status. Further exploration into societal factors that impact CPM use is warranted.

scholarly journals Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK 1987–2020)

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3697
Author(s):  
Anthony Howell ◽  
Ashu Gandhi ◽  
Sacha Howell ◽  
Mary Wilson ◽  
Anthony Maxwell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Gene Families ◽  
Mammographic Screening ◽  
Good Prognosis ◽  
Lifetime Risk ◽  
Breast Cancers ◽  
Moderate Risk ◽  
Brca1 And Brca2 ◽  
Pathogenic Variants

Clinics for women concerned about their family history of breast cancer are widely established. A Family History Clinic was set-up in Manchester, UK, in 1987 in a Breast Unit serving a population of 1.8 million. In this review, we report the outcome of risk assessment, screening and prevention strategies in the clinic and propose future approaches. Between 1987–2020, 14,311 women were referred, of whom 6.4% were from known gene families, 38.2% were at high risk (≥30% lifetime risk), 37.7% at moderate risk (17–29%), and 17.7% at an average/population risk who were discharged. A total of 4168 (29.1%) women were eligible for genetic testing and 736 carried pathogenic variants, predominantly in BRCA1 and BRCA2 but also other genes (5.1% of direct referrals). All women at high or moderate risk were offered annual mammographic screening between ages 30 and 40 years old: 646 cancers were detected in women at high and moderate risk (5.5%) with a detection rate of 5 per 1000 screens. Incident breast cancers were largely of good prognosis and resulted in a predicted survival advantage. All high/moderate-risk women were offered lifestyle prevention advice and 14–27% entered various lifestyle studies. From 1992–2003, women were offered entry into IBIS-I (tamoxifen) and IBIS-II (anastrozole) trials (12.5% of invitees joined). The NICE guidelines ratified the use of tamoxifen and raloxifene (2013) and subsequently anastrozole (2017) for prevention; 10.8% women took up the offer of such treatment between 2013–2020. Since 1994, 7164 eligible women at ≥25% lifetime risk of breast cancer were offered a discussion of risk-reducing breast surgery and 451 (6.2%) had surgery. New approaches in all aspects of the service are needed to build on these results.

Sign in / Sign up

Export Citation Format

Share Document